Eli Lilly and Company (LLY)
Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 66.2502
- Book/Share 26.5925
- PB 36.438
- Debt/Equity 1.7865
- CurrentRatio 1.5463
- ROIC 0.279
- MktCap 868318845549.0
- FreeCF/Share 10.0576
- PFCF 96.2585
- PE 47.0875
- Debt/Assets 0.3698
- DivYield 0.006
- ROE 1.0226
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | LLY | Leerink Partners | Market Perform | Outperform | -- | $1104 | Nov. 10, 2025 |
| Reiterated | LLY | BMO Capital Markets | -- | Outperform | $840 | $930 | Oct. 20, 2025 |
| Upgrade | LLY | Erste Group | Hold | Buy | -- | -- | Oct. 14, 2025 |
| Downgrade | LLY | Berenberg | Buy | Hold | -- | $830 | Sept. 17, 2025 |
| Upgrade | LLY | HSBC Securities | Reduce | Hold | -- | $700 | Aug. 27, 2025 |
| Downgrade | LLY | Daiwa Securities | Outperform | Neutral | -- | $700 | Aug. 18, 2025 |
| Downgrade | LLY | Leerink Partners | Outperform | Market Perform | -- | $715 | Aug. 7, 2025 |
| Downgrade | LLY | Erste Group | Buy | Hold | -- | -- | June 5, 2025 |
| Downgrade | LLY | HSBC Securities | Buy | Reduce | $1150 | $700 | April 28, 2025 |
| Initiation | LLY | Cantor Fitzgerald | -- | Overweight | -- | $975 | April 22, 2025 |
News
Why cutting drug prices is pushing Eli Lilly's stock toward an all-time high
Published: November 11, 2025 by: Market Watch
Sentiment: Positive
Even by dramatically lowering the prices of some of its medications, the drug giant is still outpacing its rivals and nearing a trillion-dollar valuation.
Read More
Lilly Up 18% in a Month: Should You Buy, Sell or Hold the Stock?
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly stock jumps 18% in a month as strong Q3 results, upgraded guidance and rising demand for Mounjaro and Zepbound fuel investor optimism.
Read More
GLP-1 prices are dropping: Who exactly will benefit?
Published: November 11, 2025 by: CNBC Television
Sentiment: Positive
CNBC's Bertha Coombs asks President Trump and his team at the White House's announcement on lower prices for Eli Lilly and Novo Nordisk's GLP-1 medications, if those new prices will extend to commercial plans. Half of Americans are covered by employer and private health plans, many of which don't cover GLP-1s for weight loss because of the cost.
Read More
Wall Street is Pounding the Table Over NVDA, RUN, LLY
Published: November 10, 2025 by: 24/7 Wall Street
Sentiment: Neutral
In addition, according to analysts at UBS, it sees Nvidia guiding fourth quarter revenue to a range of $63 billion to $64 billion.
Read More
Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease
Published: November 10, 2025 by: Reuters
Sentiment: Positive
MeiraGTx Holdings has signed a deal with Eli Lilly , potentially worth over $475 million, granting the pharma giant rights to its experimental gene therapy for a rare, inherited disorder that causes severe vision loss from birth.
Read More
Millions more Americans could access obesity drugs after Trump's deals with Eli Lilly, Novo Nordisk
Published: November 07, 2025 by: CNBC
Sentiment: Positive
President Donald Trump struck landmark deals with Eli Lilly and Novo Nordisk that could mark a turning point in access to their costly blockbuster obesity drugs. Medicare will start covering GLP-1s for obesity for certain patients for the first time beginning in mid-2026 – a shift that some experts say will open access to millions of older adults and could spur more employers and other private insurers to follow suit.
Read More
Eli Lilly, Novo Nordisk's Historic GLP-1 Pricing Deals - What Investors Need To Know
Published: November 07, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S and Eli Lilly and Company have agreed to slash US prices for Ozempic, Wegovy, Mounjaro, and Zepbound, expanding Medicare/Medicaid access. NVO's stock has dropped sharply in 2025, but the new deal could boost long-term revenue by increasing drug accessibility and wiping out compounded competition. Despite price cuts, LLY's strong US manufacturing presence and blockbuster tirzepatide sales position it for continued growth and potential $1T market cap.
Read More
LLY's GLP-1 Duo Boosts Sales Amid Rising Demand for Obesity Drugs
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly's Mounjaro and Zepbound continue to power growth as new launches boost momentum amid rising obesity competition.
Read More
Eli Lilly and Novo Nordisk lower GLP-1 drug costs in new deal with Trump.
Published: November 06, 2025 by: Yahoo Finance
Sentiment: Positive
About Yahoo Finance: Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life. - Get the latest news and data at finance.yahoo.com - Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO) - Follow Yahoo Finance on social: X: http://twitter.com/YahooFinance Instagram: https://www.instagram.com/yahoofinance/?hl=en TikTok: https://www.tiktok.com/@yahoofinance?lang=en Facebook: https://www.facebook.com/yahoofinance/ LinkedIn: https://www.linkedin.com/company/yahoo-finance
Read More
Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk
Published: November 06, 2025 by: CNBC
Sentiment: Positive
President Donald Trump struck landmark deals with Eli Lilly and Novo Nordisk to slash the prices of their blockbuster weight loss drugs. Under the agreements, the monthly out-of-pocket cost of popular injections and upcoming pills could range from $50 to $350, depending on the dosage and insurance coverage a patient has.
Read More
Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans
Published: November 06, 2025 by: PRNewsWire
Sentiment: Neutral
Medicare beneficiaries with obesity or overweight will have access to Zepbound and orforglipron, if approved, at $50 a month INDIANAPOLIS , Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an agreement with the U.S. government to expand access to its obesity medicines and reduce patient costs. The agreement builds on Lilly's longstanding commitment to finding solutions with policymakers that improve access to life-changing medicines.
Read More
Lilly, Novo Will Lower Obesity Drug Prices in Trump Deal
Published: November 06, 2025 by: Bloomberg Markets and Finance
Sentiment: Positive
Eli Lilly & Co. and Novo Nordisk A/S cut a deal with the Trump administration to lower prices on their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. President Donald Trump spoke about it in the Oval Office.
Read More
Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
Published: November 06, 2025 by: CNBC
Sentiment: Positive
President Donald Trump announced deals with Eli Lilly and Novo Nordisk to slash the prices of some of their obesity drugs, including upcoming pills, in a landmark effort to expand access to the costly blockbuster treatments. The agreements will lower prices of GLP-1 drugs on Medicare and Medicaid and offer the treatments directly to consumers at a discount on a website the Trump administration is launching in January 2026 called TrumpRx.gov.
Read More
Trump White House confirms pricing deal with weight-loss-drug giants Eli Lilly, Novo Nordisk
Published: November 06, 2025 by: Market Watch
Sentiment: Positive
President Donald Trump's administration confirmed Thursday that it has reached a deal with Eli Lilly and Novo Nordisk that aims to deliver lower prices for their popular GLP-1 drugs to certain Medicare and Medicaid beneficiaries and to users of TrumpRx.gov, the administration's new direct-to-consumer website.
Read More
Here's Why Eli Lilly (LLY) is a Strong Momentum Stock
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Lilly and Novo Nordisk near White House deal on obesity drug prices, Endpoints New reports
Published: November 04, 2025 by: Reuters
Sentiment: Positive
Eli Lilly and Novo Nordisk are preparing to announce new drug pricing deals with the White House, including for their blockbuster weight loss drugs, in return for coverage of products under Medicare, Endpoints New reported on Tuesday, citing sources familiar with the matter.
Read More
International Markets and Lilly (LLY): A Deep Dive for Investors
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Explore how Lilly's (LLY) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Read More
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Eli Lilly Has A Solid Upside Now After Its Q3 Earnings
Published: October 31, 2025 by: Seeking Alpha
Sentiment: Positive
Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin analogs. LLY posted a 54% YoY revenue jump and a 19% EPS beat, with management raising both sales and EPS guidance for the year. A strengthened drug pipeline, particularly for orforglipron's Phase III success, de-risks future earnings and promises sustained growth beyond 2027.
Read More
Eli Lilly's obesity and diabetes treatments fuel growth and spark bidding war
Published: October 31, 2025 by: Fast Company
Sentiment: Positive
The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.
Read More
Eli Lilly and Company (LLY) Q3 2025 Earnings Call Transcript
Published: October 30, 2025 by: Seeking Alpha
Sentiment: Neutral
Eli Lilly and Company ( LLY ) Q3 2025 Earnings Call October 30, 2025 10:00 AM EDT Company Participants Mike Czapar - Director of Investor Relations David Ricks - Chairman, CEO & President Lucas Montarce - Executive VP & CFO Daniel Skovronsky - EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology Patrik Jonsson - Executive VP & President of Lilly International Ilya Yuffa - Executive VP and President of Lilly USA & Global Customer Capabilities Anne White - Executive VP & President of Lilly Neuroscience Kenneth Custer - Executive VP & President of Lilly Cardiometabolic …
Read More
Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year sales and earnings outlook.
Read More
Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Eli Lilly Boosts Its Outlook on High Demand for Popular Weight-Loss Drugs
Published: October 30, 2025 by: Investopedia
Sentiment: Positive
Strong sales of Eli Lilly's weight-loss treatments Mounjaro and Zepbound helped power strong quarterly earnings, and the drugmaker boosted its outlook.
Read More
Eli Lilly Q3 earnings and revenue top estimates, boosted by weight loss drug demand
Published: October 30, 2025 by: Proactive Investors
Sentiment: Positive
Eli Lilly and Co (NYSE:LLY) on Thursday reported third quarter 2025 financial results that handily beat Wall Street forecasts, as the company continued to see strong demand for its weight loss drug Zepbound and diabetes treatment Mounjaro. The pharmaceutical giant's revenue for the quarter rose 54% year over year to $17.60 billion, surpassing the analyst consensus estimate of $16.01 billion, according to data provided by LSEG.
Read More
Eli Lilly Blows Away Q3 Earnings Expectations
Published: October 30, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Eli Lilly (NYSE: LLY) delivered a commanding third quarter, posting earnings and revenue that significantly exceeded expectations while raising full-year guidance.
Read More
Eli Lilly, Walmart to offer first retail pickup option for discounted vials of weight loss drug Zepbound
Published: October 29, 2025 by: CNBC
Sentiment: Positive
Eli Lilly and Walmart said they have teamed up to boost access to the pharma giant's weight loss drug Zepbound, allowing U.S. patients to access vials of the blockbuster injection at direct-to-consumer prices through retail locations for the first time. Starting in mid-November, cash-paying patients with a prescription can purchase single-dose vials of Zepbound at discounts of 50% or more through the retailer's nearly 4,600 pharmacy locations or via home delivery.
Read More
What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?
Published: October 29, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY's rapid dealmaking spree across biotech and gene therapy aims to expand its pipeline beyond cardiometabolic drugs and fuel long-term growth.
Read More
Lilly and Walmart launch first retail pick-up option for weight-loss drug
Published: October 29, 2025 by: Reuters
Sentiment: Positive
Eli Lilly and Walmart said on Wednesday they are partnering to expand access to single-dose vials of Lilly's weight-loss drug Zepbound, which will be offered for pick-up at Walmart pharmacies nationwide by mid-November.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000